Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma

Cancer

Volumn 94, Issue 7, 2002, Pages 1961-1967

  Gronlund, Bo ^a   Hgdall, Claus ^a   Hansen, Heine H ^a   Engelholm, Svend A ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Aged; Carboplatin; Elderly; Epithelial ovarian carcinoma; Overall survival; Paclitaxel; Progression free survival; Recurrence; Second line treatment; Topotecan

Indexed keywords

CARBOPLATIN; CYTOSTATIC AGENT; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MULTIVARIATE ANALYSIS; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA;

AGE FACTORS; AGED; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOPOTECAN;

EID: 0036533832     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10385     Document Type: Article

References (30)

1. The aging of the human species
2. Cancer burden in the aged: An epidemiologic and demographic overview
3. Chemotherapy of advanced ovarian cancer
4. Drug therapy for gynaecological cancer in older women
5. Advanced epithelial ovarian cancer: 1998 Consensus statements
6. Gynecologic cancer in the elderly
7. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
8. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer
9. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study
10. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
11. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
12. Reporting results of cancer treatment
13. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
14. Trends in United States ovarian cancer mortality, 1979-1995
15. Rising ovarian cancer mortality in the elderly: A manifestation of differential survival
16. Ovarian cancer in the elderly: An analysis of surveillance, epidemiology, and end results program data
17. Ovarian cancer. Survival and treatment differences by age
18. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience
19. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
20. National survey of ovarian carcinoma, IV: Patterns of care and related survival for older patients
21. Age - Is it a risk factor in ovarian cancer?
22. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience
23. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies
24. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
25. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary
26. Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner?
27. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups
28. Cancer chemotherapy in the older patient: What the medical oncologist needs to know
29. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: A phase II study
30. The treatment of recurrent ovarian carcinoma: Balancing patient desires, therapeutic benefit, cost containment and quality of life